Drug Trial Radar · NCT07152340
The Safety and Efficacy of Sequential Hormone Therapy and IBI311 Therapy in Patients With Active Moderate to Severe TAO in the Initial Treatment.
Last checked: Nov 19, 2026Latest source record: Sep 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
64
Planned (sponsor's estimate)
Start
Apr 10, 2025
Primary completion
Apr 30, 2027
Study completion May 1, 2030
Sponsor
- Lead sponsor
- Shanghai Changzheng HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 3, 2025
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Thyroid-associated ophthalmopathy (TAO) is an organ-specific autoimmune disease closely related to thyroid disease, which leads the incidence of orbital disease in adults and is the most common cause of diffuse toxic goiter (Graves disease, GD). The clinical manifestations of TAO are complex and varied. In severe cases, it may seriously impair visual function, affect daily life, and even cause corneal ulceration, perforation, and blindness. Therefore, a reasonable and effective treatment plan should be chosen according to the degree of TAO. Tetuzumab (IBI311) is a fully human monoclonal insulin-like growth factor-1 receptor inhibitory antibody. It has binding activity against IGF-1R positive cells, can block the binding of IGF-1 and IGF-2 to IGF-1R, and has a dose-dependent effect. It can inhibit the proliferation of HT29 cells caused by the activation of the IGF-1R signaling pathway. Meanwhile, it can dose-dependently inhibit the proliferation of orbital fibroblasts and the secretion of hyaluronic acid (HA) in patients with TAO. However, there are still significant gaps in the existing research evidence: the lack of head-to-head studies of temumab and glucocorticoids. The aim of this clinical study is to: 1. To evaluate the efficacy of IBI311 treatment in patients with active moderate to severe TAO in the initial treatment. 2. To observe the safety of IBI311 treatment in patients with active moderate to severe TAO in the initial treatment. 3. Head-to-head comparison of sequential hormone therapy and IBI311 therapy in patients with active moderate to severe TAO in the initial treatment.
Conditions
- Thyroid Associated Ophthalmopathies
Interventions
IBI311Drug
IBI311 is a fully human anti-IGF-1R mAb. IBI311 will be provided in single-dose 10-mL glass vials as a Injection solution containing.
GlucocorticoidsDrug
500mg methylprednisolone was intravenously injected once a day for 3 consecutive days. The next treatment was carried out with an interval of 2 weeks for a total of 8 times.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of participants who were overall treatment responders ater 4 times and at the end of treatmentTime frame: up to 24 weeks
- Percentage of participants who were CAS categorical responders after 4 times and at the end of the treatmentTime frame: up to 24 weeks
- Percentage of participants who were diplopia responders after 4 times and at the end of the treatmentTime frame: up to 24 weeks
- Percentage of participants who were proptosis responders after 4 times and and the end of the treatmentTime frame: up to 24 weeks
- Percentage of participants who were ATA categorical responders after 4 times and at the end of the treatmentTime frame: up to 24 weeks
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Shanghai Changzheng Hospital
Changhua, Shanghai Municipality, China · Recruiting
Shanghai Changzheng Hospital
Shanghai, Shanghai Municipality, China · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.